EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer

Md Jashim Uddin iD, Justin Han-Je Lo, Mukesh K Gupta iD, Thomas A Werfel iD, Abu Asaduzzaman iD, Connor G Oltman, Eva F Gbur iD, Mohammed T Mohyuddin iD, Farhana Nazmin, Md Saidur Rahman, Ahan Jashim, Brenda C Crews und 5 weitere

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c00695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Md Jashim Uddin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Nanoparticles, Breast Neoplasms, Polymers, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the coencapsulation of fluorocoxib Q (FQ) and chemocoxib A (CA) in micellar nanoparticles (FQ-CA-NPs) of a new PPS135-b-POEGA17 diblock polymer, which exhibited a hydrodynamic diameter of 109.2 ± 4.1 nm and a zeta potential (ζ) of -1.59 ± 0.3 mV. The uptake of FQ-CA-NPs by 4T1 mouse mammary cancer cells and intracellular cargo release were assessed by fluorescence microscopy that resulted in increased fluorescence in 4T1 cells compared to cells pretreated with celecoxib. The viability of primary human mammary epithelial cells (HMECs) or 4T1 mouse mammary carcinoma cells treated with FQ-CA-NPs were assessed, which showed decreased growth of 4T1 breast cancer cells but showed no effect on the growth of primary human mammary epithelial cells (HMECs). Intravenous dosing of FQ-CA-NPs in mice enabled ROS-induced cargo (FQ and CA) release and fluorescence activation of FQ and resulted in increased fluorescence in breast tumors compared to the tumors of animals pretreated with tempol or celecoxib, and minimum fluorescence was detected in the tumors of animals treated with nothing or empty-NPs. In addition, tumor tissues from treated animals were analyzed ex vivo by liquid chromatography-mass spectrometry (LC-MS)/MS, and identified increased levels of cargo delivery and retention in the tumor compared to tempol- or celecoxib-pretreated animal tumors. These in vivo and ex vivo results confirmed the targeted delivery of loaded NPs followed by ROS-mediated cargo release and fluorescence activation for targeted visualization of drug delivery in breast tumors and CA-induced therapeutic effect in an in vivo tumor growth inhibition assay and an ex vivo hematoxylin and eosin (H&E) staining of tumor tissues. Thus, coencapsulation of FQ and CA into polymeric micellar nanoparticles (FQ-CA-NPs) enabled their ROS-sensitive release followed by fluorescence activation and COX-2-dependent tumor targeting and retention in the visualization of CA delivery in solid breast tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesBreast NeoplasmsPolymersDrug Delivery SystemsAnimalsFemaleMiceHumansCell Line, TumorMicellesCelecoxibMice, Inbred BALB CReactive Oxygen Species

Stichwörter der Autor:innen

chemocoxib Adrug deliveryfluorocoxib Qmicellar nanoparticlestumor imaging

Substanzen

PolymersMicellesCelecoxibReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee 37232, United States.
  • Departments of Electrical and Computer Engineering, Wichita State University School of Engineering, Wichita, Kansas 67260, United States.
  • Departments of Biochemistry, Chemistry and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

ORCID-Profile: Md Jashim Uddin, Mukesh K Gupta, Thomas A Werfel, Abu Asaduzzaman, Eva F Gbur, Mohammed T Mohyuddin, Jamie E Klendworth, Lawrence J Marnett, Craig L Duvall

Förderung

  • NIBIB NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
  • Phi Beta Psi Sorority

Zitieren

APA

Uddin, M. J., Lo, J. H., Gupta, M. K., Werfel, T. A., Asaduzzaman, A., Oltman, C. G., Gbur, E. F., Mohyuddin, M. T., Nazmin, F., Rahman, M. S., Jashim, A., Crews, B. C., Kingsley, P. J., Klendworth, J. E., Marnett, L. J., Duvall, C. L., & Cook, R. S. (2025). Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00695

Vancouver

Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, et al. Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00695

BibTeX
@article{Uddin2025,
  author = {Uddin, Md Jashim and Lo, Justin Han-Je and Gupta, Mukesh K and Werfel, Thomas A and Asaduzzaman, Abu and Oltman, Connor G and Gbur, Eva F and Mohyuddin, Mohammed T and Nazmin, Farhana and Rahman, Md Saidur and Jashim, Ahan and Crews, Brenda C and Kingsley, Philip J and Klendworth, Jamie E and Marnett, Lawrence J and Duvall, Craig L and Cook, Rebecca S},
  title = {Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c00695}
}
Kostenlos starten →